Identification of Drug-Targetable Genes for Eczema and Dermatitis Using Integrated Genomic and Proteomic Approaches

Area of Science:

• Genetics and Genomics
• Dermatology
• Pharmacology

Background:

• Eczema and dermatitis are prevalent inflammatory skin conditions causing significant morbidity.
• Identifying drug-targetable genes is crucial for developing effective treatments.

Purpose of the Study:

• To identify drug-targetable genes associated with eczema/dermatitis through genetic analysis.
• To validate potential causal relationships and explore therapeutic targets.

Main Methods:

• Meta-analysis of genome-wide association studies (GWAS) involving over 57,000 cases and 896,000 controls.
• Mendelian randomization (MR) analyses using cis-expression quantitative trait loci (eQTL) data from blood and skin tissues.
• Bayesian colocalization, proteomic MR, protein-protein interaction (PPI) network analysis, and correlation analysis.

Main Results:

• Identified 2532 drug-targetable genes. Five genes (SLC22A5, NOTCH4, AGER, HLA-DRB5, EHMT2) showed causal links to eczema/dermatitis.
• AGER demonstrated a strong causal relationship and was associated with reduced eczema/dermatitis risk (OR 0.995).
• AGER interacts with NOTCH4 and cytokines, suggesting a role in inflammatory pathways.

Conclusions:

• AGER is a promising drug target for reducing eczema/dermatitis risk.
• The study provides a foundation for developing novel, targeted therapies for these common skin conditions.